CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560
Company Information
CymaBay Therapeutics (Nasdaq: CBAY)
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.
Stock Information
| Last | Change | Volume |
Company Information
Investor Relations
LifeSci Advisors, LLC
Hans Vitzthum
(617) 430-7578
Hans@LifeSciAdvisors.com
Recent News
Upcoming Event
Jun
17
2021
SVB Leerink CybeRx Series: “Liver Disease Day” Conference
June 17, 2021